Pharma & Biotech Industry Analysis, from Thought Leaders
Refine Search
Pharmaceutical
For more than a decade, analysts and industry insiders have discussed the potential impact of data in healthcare, but what has actually changed, and what changes are yet to come? 7 March 2017
Biotechnology
Historically, we have seen combination therapies used to treat illnesses such as malaria, tuberculosis (TB) and AIDS. In all three of these cases, combination therapies, or ‘drug cocktails’ helped to fight the sickness more effectively than a single agent treatment, writes Lan Huang, chief executive of USA-based BeyondSpring, in an overview of this field. 27 February 2017
Biotechnology
Dr Nicola Davies looks at some of the latest updates in an area of oncology research with considerable potential and risk. 20 February 2017
Biosimilars
Dr Nicola Davies explores how pharma companies can secure the future of biobetters in the presence of biosimilars and increased payer scrutiny on high prices. 14 February 2017
Pharmaceutical
Our most detailed article yet on what we know, and do not yet know, about how the new US President could affect pharma. 6 February 2017
Pharmaceutical
Donald Trump’s warnings on drug prices and the tougher stance being taken by governments in Japan and Europe on paying for medicines make this a worrying time for pharma companies, as they nervously keep an eye on leaders’ pledges, policy changes and payer decisions in these mature markets. 30 January 2017
Pharmaceutical
Emily Walsh from the Mesothelioma Cancer Alliance looks at the progress made in the first year of the Cancer Moonshot and considers what lies ahead for the program. 24 January 2017
Pharmaceutical
Dr Sam Samaratunga, a GP and life sciences lawyer with Keystone Law, looks at the proposed changes to arrangements for evaluating and funding drugs and other health technologies appraised through NICE’s Technology Appraisal (TA) and Highly Specialized Technologies (HST) programs. 17 January 2017
Pharmaceutical
Dr Nicola Davies explores the market access steps taken by companies such as Takeda to make medicines available and affordable for high priority patient populations. 10 January 2017
Pharmaceutical
What more does pharma and biotech know now about the implications of Brexit six months after the UK population voted to leave the European Union? 19 December 2016
Pharmaceutical
A jack-of-all-trades company is one that creates and maintains its presence in a range of therapy areas and healthcare business domains. In some ways, there are merits to diversification and to having a wide product portfolio. 12 December 2016
Pharmaceutical
It is no longer a question of if a digital revolution will happen in health care. 1 December 2016
Biotechnology
With so many predictions and promises being made in this much-talked about area of pharma and medicine, Dr Nicola Davies questions whether we truly are entering a new era of personalized medicine. 25 November 2016
Pharmaceutical
The Russian pharmaceutical market is one of the fastest growing in the world, and this overview describes the main regulatory trends, associated legal risks and opportunities for pharma manufacturers in 2016-2017 in Russia. 21 November 2016
Pharmaceutical
Speculation is rife about what Donald Trump’s election win means for pharma and health care in the USA, but what of its potential impact on the industry in Europe? Novasecta’s Salma Ajraoui analyzes the issue. 15 November 2016
Pharmaceutical
Results from a survey analysing the prescribing behavior of 500 European physicians treating patients with advanced non-small cell lung cancer (NSCLC) have been released. 9 November 2016
Pharmaceutical
My knowledge of doctors and hospitals in Japan is above average, having lived here for 46 years while working in the health care industry and receiving medical care, including four operations, says long-time Japanese industry watcher P Reed Maurer, president of International Alliances Limited. 31 October 2016
Pharmaceutical
Imagine a world where the most common and routine operations are made all but impossible without a severe risk of death from infection. Where hip replacements, caesarean sections and bone repair are no longer viable and we are cast back 100 years to a time before antibiotics. It is a worrying thought, but such fears are becoming a real possibility. Joel Levy looks at what is being done to address the issue of antimicrobial resistance. 17 October 2016
Pharmaceutical
The number of people dying from opioid or heroin overdoses has nearly quadrupled in the US since the beginning of century leading to increased scrutiny of laws around prescription opioids and calls on the pharma industry to take more responsibility. Joel Levy takes an in-depth look at the issue. 3 October 2016
Pharmaceutical
When Mary Mitchell-O’Connor, Ireland’s Minister of Jobs, Enterprise and Innovation, was speaking at a Dublin conference last week, she could have used countless statistics to demonstrate the strength of her country’s pharmaceutical sector. 26 September 2016
Biotechnology
A Feature analyzing M&A, licensing and partnerships in gene editing as CRISPR therapeutics enter the market and present new opportunities for pharma growth. 15 November 2024
Pharmaceutical
Life science investors can be divided into two groups: those who bought Novo Nordisk stock before GLP-1s hit the big time, and those who wish they had. 10 November 2024
Biotechnology
Antibody-drug conjugates (ADCs) represent a transformative class of cancer therapy that combine the targeting ability of antibodies with the cell-killing potential of cytotoxic drugs. 15 October 2024
Pharmaceutical
F2G’s September $100m funding round provides the company with crucial funds to
renavigate approval of its lead drug, olorofim. The substantial financing also
highlights the paucity of novel antifungal products in the clinic. 3 October 2024
Pharmaceutical
As stakeholders in the pharmaceutical industry, we all have a responsibility to ensure life-saving treatments promptly and safely reach patients regardless of where they live. To this end, by integrating early access programs and other less conventional strategies into a company’s business model for drug distribution, patients who are suffering from life-threatening conditions can gain access to needed treatments in regions where there is a lack of drug accessibility, while at the same time offering benefits to pharmaceutical companies. 2 October 2024
Pharmaceutical
A Feature on M&A, licensing and partnerships hotting up in inflammatory diseases as new targets present new opportunities for future growth. 30 September 2024
Pharmaceutical
Scarcely anything unites lawmakers in America these days, but the ostensible iniquities of Big Pharma could be a rare exception. 22 September 2024
Pharmaceutical
The upcoming European Society for Medical Oncology (ESMO) Congress 2024 should provide a reminder—if it were needed—of the pace of innovation in the development of new medicines for cancer. 10 September 2024
Pharmaceutical
CytoReason’s $80 million venture round may not have been the biggest in July, but it is one of a growing number of investor bets on AI powered drug discovery this year. 7 August 2024
Pharmaceutical
An Analysis of M&A activity in the CNS space. 26 July 2024
Pharmaceutical
The biopharmaceutical supply chain plays a pivotal role in ensuring the seamless delivery of therapeutics to patients. However, pharmaceutical supply chains face several challenges, including regulatory complexities, global competition, and the need for innovation. 26 July 2024
Pharmaceutical
Anticipation had been building for many weeks, but when the UK’s general election finally took place on 4 July, the outcome felt entirely inevitable. 9 July 2024
Biotechnology
The annual meeting of the American Society of Clinical Oncology (ASCO) is set to commence on 2 June in Chicago, with the highly anticipated plenary session taking place on the Sunday. 22 May 2024
Pharmaceutical
An analysis of the investment activity of Novartis in recent years. 5 April 2024
Pharmaceutical
An analysis of recent pharma activity in the metabolic diseases field and why obesity is a hot topic amongst investors. 8 March 2024
Pharmaceutical
When James Burt, the chief executive of lifecycle management healthcare company Pharmanovia, looks back at the mood in the pharma industry in 2023, he is happy to say that he is already experiencing a greater sense of optimism in 2024. 27 February 2024
Pharmaceutical
Danish drugmaker Lundbeck has its eye on steady growth over the medium term, a strategy which new chief executive Charl van Zyl believes could be key to the firm’s future success. 12 February 2024
Biotechnology
By Barbara Obstoj-Cardwell. Editor
In full year 2023, the total number of mergers and acquisitions (M&A) in the pharma and biotech sectors was 105, compared with 109 in 2022 and just 92 in 2021, according to tracking by The Pharma Letter (TPL). 4 January 2024
Biosimilars
In the two decades since biosimilars emerged on the world stage, their evolution has brought acceptance of the critical role they can play in making life-changing therapies more affordable. 22 December 2023
Pharmaceutical
A feature analyzing recent pharma activity in the hepatology field and why NASH remains unchartered territory. 20 December 2023
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
A US biotech company dedicated to creating oral drugs with an emphasis on indications in virology and immunology.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze